Knight Therapeutics Inc
TSX:GUD
Relative Value
The Relative Value of one GUD stock under the Base Case scenario is 6.14 CAD. Compared to the current market price of 5.82 CAD, Knight Therapeutics Inc is Undervalued by 5%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
GUD Competitors Multiples
Knight Therapeutics Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
CA |
K
|
Knight Therapeutics Inc
TSX:GUD
|
588.8m CAD | 1.8 | -35 | 8.5 | 75.4 | |
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
US |
Eli Lilly and Co
NYSE:LLY
|
717.6B USD | 21 | 136.9 | 61.8 | 71 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
3.9T DKK | 16.8 | 46.5 | 34 | 37.1 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
360.9B USD | 4.4 | 8.9 | 11.9 | 15.7 | ||
US |
Merck & Co Inc
NYSE:MRK
|
324.7B USD | 5.3 | 140.8 | 33.5 | 53.1 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
188.4B GBP | 5.2 | 39.7 | 140.8 | 225.8 | ||
CH |
Novartis AG
SIX:NOVN
|
181.7B CHF | 4.3 | 13.4 | 9.8 | 16.3 | ||
CH |
Roche Holding AG
SIX:ROG
|
170.7B CHF | 2.9 | 14.8 | 8.5 | 10.1 | ||
US |
Pfizer Inc
NYSE:PFE
|
156.4B USD | 2.7 | 73.8 | 11 | 16.3 |